Pharos iBio Partners with Yonsei University for "AI-Based Anti-Aging Research" Collaboration

Joint Research on Disease Mechanism Analysis
Expanding Research Utilizing AI Drug Development Platform

Pharos iBio, an artificial intelligence (AI)-based drug discovery company, is partnering with Yonsei University to collaborate on AI-powered anti-aging research.

From the left, Pharos iBio, Yonsei University Advanced Bioindustry Convergence Research Group CI. Pharos iBio

On March 16, Pharos iBio announced that it had signed a memorandum of understanding (MOU) with the Yonsei University Advanced Bioindustry Convergence Research Group for joint research and talent development in the fields of AI and anti-aging.

Through this agreement, the two organizations will pursue joint research and the identification of new research projects in next-generation anti-aging and biohealth sectors. The collaboration will also encompass AI-based disease mechanism analysis and the development of biohealth professionals through industry-academia cooperation.

Pharos iBio has utilized its proprietary AI drug development platform, Chemiverse, to analyze the mechanisms underlying rare and intractable diseases and to design new drug candidates. With this partnership, the company plans to expand its research to analyze the mechanisms of aging-related diseases and to explore novel therapeutic approaches.

The Yonsei University Advanced Bioindustry Convergence Research Group, designated as a specialized graduate school for advanced bioindustry by the Ministry of Trade, Industry and Energy, operates technology convergence and industry-academia cooperation projects in the biohealth industry.

Based on the Chemiverse AI drug development platform, Pharos iBio has discovered the acute myeloid leukemia treatment candidate "Lasmotinib" and the refractory solid tumor treatment candidate "PHI-501." Lasmotinib has completed global Phase 1 clinical trials, while PHI-501 is currently undergoing Phase 1 clinical trials in Korea.

This content was produced with the assistance of AI translation services.